Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Murphy

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
BMJ Open|October 11, 2014
NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's diseaseBrian Lawlor, Sean Kennelly, Sarah O'Dwyer, et al.
Trials|August 7, 2019
Update to the study protocol, including statistical analysis plan, for the multicentre, randomised controlled OuTSMART trial: a combined screening/treatment programme to prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodiesDominic Stringer, Leanne M Gardner, Janet L Peacock, et al.
Frontiers in Oncology|February 26, 2021
A Position Statement on the Utility of Interval Imaging in Standard of Care Brain Tumour Management: Defining the Evidence Gap and Opportunities for Future ResearchThomas C Booth, Gerard Thompson, Helen Bulbeck, et al.
Lancet (London, England)|February 16, 2024
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trialAndrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
Eclinicalmedicine|January 23, 2023
Optimized immunosuppression to prevent graft failure in renal transplant recipients with HLA antibodies (OuTSMART): a randomised controlled trialDominic Stringer, Leanne Gardner, Olivia Shaw, et al.
The Lancet. Rheumatology|January 23, 2026
Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trialAndrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
European Heart Journal|August 30, 2020
Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trialShouvik Haldar, Habib Rehman Khan, Vennela Boyalla, et al.
Trials|July 17, 2019
Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocolMariam Al-Laith, Marianna Jasenecova, Sonya Abraham, et al.
Nature Genetics|February 27, 2007
A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosisChiea C Khor, Stephen J Chapman, Fredrik O Vannberg, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
BMJ Open|October 11, 2014
NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's diseaseBrian Lawlor, Sean Kennelly, Sarah O'Dwyer, et al.
Trials|August 7, 2019
Update to the study protocol, including statistical analysis plan, for the multicentre, randomised controlled OuTSMART trial: a combined screening/treatment programme to prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodiesDominic Stringer, Leanne M Gardner, Janet L Peacock, et al.
Frontiers in Oncology|February 26, 2021
A Position Statement on the Utility of Interval Imaging in Standard of Care Brain Tumour Management: Defining the Evidence Gap and Opportunities for Future ResearchThomas C Booth, Gerard Thompson, Helen Bulbeck, et al.
Lancet (London, England)|February 16, 2024
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trialAndrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
Eclinicalmedicine|January 23, 2023
Optimized immunosuppression to prevent graft failure in renal transplant recipients with HLA antibodies (OuTSMART): a randomised controlled trialDominic Stringer, Leanne Gardner, Olivia Shaw, et al.
The Lancet. Rheumatology|January 23, 2026
Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trialAndrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
European Heart Journal|August 30, 2020
Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trialShouvik Haldar, Habib Rehman Khan, Vennela Boyalla, et al.
Trials|July 17, 2019
Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocolMariam Al-Laith, Marianna Jasenecova, Sonya Abraham, et al.
Nature Genetics|February 27, 2007
A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosisChiea C Khor, Stephen J Chapman, Fredrik O Vannberg, et al.
Pageof 9